Colorado PDAB

CANN raises questions about Colorado's PDAB ongoing board activity, focusing on HB23-1225 drug eligibility thresholds, the effectiveness of upper payment limits for patient out-of-pocket affordability, formulary protection gaps, and patient engagement via the PDAAC toolkit and Community Partner Network.

Comment on Colorado PDAB's November 2025 meeting addressing ongoing UPL development concerns, pricing methodology issues, and patient access implications.

Comment on Colorado PDAB's November 11, 2025 meeting addressing ongoing UPL development, cost-benefit analysis concerns, and patient access protection advocacy.

Comment on Colorado PDAB's UPL development progress, addressing ongoing concerns about implementation timeline, enforcement mechanisms, and patient access protections.

Comment raising concerns about Colorado PDAB's UPL setting process, including pricing methodology, patient impact assessment, and safety-net provider considerations.

Comment on Colorado PDAB's ongoing UPL development addressing methodology concerns, cost-shifting risks, and impacts on safety-net providers and Medicaid programs.

Comment on Colorado PDAB's rulemaking process for UPL development, addressing procedural concerns, methodology transparency, and stakeholder engagement.

Comment on Colorado PDAB's cost investigation and data analysis methodology, raising concerns about analytical rigor, data sources, and implications for UPL calculations.

Comment on Colorado General Assembly PDAB funding proposals, raising concerns about resource allocation for UPL implementation and potential impacts on state healthcare programs.

Extensive comment analyzing Colorado PDAB's cost-benefit analysis for Upper Payment Limits, providing detailed critique of methodology, data assumptions, and potential unintended consequences for drug access and safety-net care.

Comment expressing ongoing concerns about Colorado PDAB's Upper Payment Limit development, including insufficient patient impact assessment and inadequate safety-net provider considerations.

Comment on Colorado PDAB's rulemaking process for Upper Payment Limits, raising concerns about procedural transparency, stakeholder engagement, and potential unintended consequences for patient access.

Comment on Colorado PDAB's Upper Payment Limit development, addressing budgetary impacts on Medicaid, lack of clarity on problems UPLs solve, and concerns about discriminatory pricing methodologies.

Written comment addressing Colorado PDAB's ongoing affordability review process, raising concerns about methodology, patient impact assessment, and safety-net program protections.

Detailed comment opposing Colorado PDAB's GENVOYA affordability review, citing insufficient patient engagement (2.5% survey response rate) and threats to safety-net provider funding.

Extensive regulatory analysis request examining Colorado PDAB's proposed rulemaking for UPL implementation, providing detailed critique of methodology, legal authority, and patient impact considerations.

Community coalition letter opposing Colorado PDAB's affordability review of GENVOYA (HIV antiretroviral), warning that upper payment limits threaten HIV treatment access and 340B program funding for safety-net providers.

Comment on Colorado PDAB's September 2023 meeting addressing ongoing affordability review concerns and advocacy for patient-protective review criteria.